June 16, 2020 / 5:43 PM / 18 days ago

BRIEF-Merck And Pfizer's Steglatrotm Meets Primary Endpoint

June 16 (Reuters) - Merck & Co Inc:

* MERCK AND PFIZER’S SGLT2 INHIBITOR STEGLATROTM (ERTUGLIFLOZIN) MEETS PRIMARY ENDPOINT IN VERTIS CV TRIAL FOR PATIENTS WITH TYPE 2 DIABETES AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE

* MERCK & CO INC - KEY SECONDARY ENDPOINTS OF SUPERIORITY FOR ERTUGLIFLOZIN VERSUS PLACEBO WERE NOT MET

* MERCK - SAFETY PROFILE OF STEGLATRO WAS CONSISTENT WITH THAT REPORTED IN PREVIOUS STUDIES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below